Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2014

View Archived Issues

Morphine tolerance reversed by blocking neuropeptide FF2 receptor

MYL3 gene mutation identified in hypertrophic cardiomyopathy pedigree

SomaGenics receives NIH funding to develop RNA technologies

Valneva begins phase II trial of VLA-84

Chimerix and ContraVir establish strategic collaboration for CMX-157

Merck & Co. expands oncology portfolio with acquisition of OncoEthix

Inovio Pharmaceuticals begins DNA immunotherapy trial for breast, lung and pancreatic cancer

Curis initiates phase I trial of CUDC-907 in patients with solid tumors

GlaxoSmithKline varicella zoster vaccine reduces incidence of shingles in phase III trial

Fate Therapeutics reports interim data from phase II trial of Prohema

Phase II trial of IPH-2201 begins in squamous cell carcinoma of the oral cavity

SciClone to commercialize clevidipine and bivalirudin in China

IND submitted for phase II study of NS2 for noninfectious anterior uveitis

Immunogenicity and safety of the Ebola virus vaccine cAd3-EBO in a phase I trial

University of Leicester patent describes compounds for bacterial infections

Xencor and Novo Nordisk form collaboration using Xencor's XmAb technologies

Marina Biotech and MiNA Therapeutics form agreement for saRNA-based therapeutics

Roche to acquire Dutalys

FDA approves AbbVie's Viekira Pak for chronic genotype 1 HCV infection

NETRIS Pharma creates first humanized monoclonal antibody against netrin-1

Bayer Schering Pharma describes novel thrombin inhibitors

Temple University prepares and tests novel glutamate uptake modulators

K(Ca)3.1 channel activators reported in Astellas Pharma patent

Xiapex receives positive opinion by CHMP for Peyronie's disease

Baxter applies for FDA approval of BAX-111 for Von Willebrand disease

First U.S. approval granted for nivolumab injection for metastatic melanoma

European marketing approval granted to Clinuvel's Scenesse

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...